The bigger picture: GLP-1 insurance coverage trends Understanding the broader insurance landscape helps you anticipate future changes to your coverage and plan accordingly
Most patients can schedule their visit within 1-2 days
Weight Loss in Clinical Trials Researchers randomly assigned participants to take a daily pill containing 25 mg of semaglutide or a placebo
Weight Loss Results: What the Data Shows When it comes to shedding pounds, injectable GLP-1s deliver superior results based on extensive clinical trials: Injectable semaglutide (Wegovy ) : 15-17% average body weight loss Injectable tirzepatide (Mounjaro /Zepboun d) : Up to 22.5% average body weight loss FDA-approved oral semaglutide: 13.6-16.6% average body weight loss Compounded ODT formulations : No published clinical trial data available A real-world comparison study found that patients on injectable semaglutide lost 1.62kg more than those on FDA-approved oral semaglutide over 26 weeks, which was not significant

Do not use if you: Have a seizure disorder or history of seizures Have uncontrolled high blood pressure Have bulimia or anorexia nervosa Use chronic opioids or are in acute opioid withdrawal Used an MAOI within 14 days Are pregnant Use caution and discuss risks if you have a history of bipolar disorder, significant head injury, stroke, liver disease, narrowangle glaucoma, or if youre reducing alcohol or sedative use